ThinkCyte
ThinkCyte is a Japanese biotechnology company that develops and commercializes AI-powered, label-free cell analysis and sorting instruments based on its proprietary Ghost Cytometry technology. It serves biopharmaceutical companies, academic research institutions, and healthcare organizations across cell therapy, drug discovery, and disease profiling applications.
- Company typePrivate
- Founded2016
- HeadquartersHongo, Japan
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ThinkCyte does
ThinkCyte K.K. is a Tokyo-headquartered biotechnology company founded in February 2016 by Waichiro Katsuda (CEO) and Sadao Ota (CSO), with a US headquarters in Redwood City, California. The company develops and commercializes Ghost Cytometry, a proprietary AI-based, label-free cell analysis and sorting technology that integrates ultrafast compressive imaging, machine learning, and microfluidics to characterize and sort single cells based on morphological phenotype rather than fluorescent labels. Its flagship product, VisionSort, is described as the world's first AI-based dual-mode platform combining conventional fluorescence flow cytometry with high-dimensional morphological profiling, and was commercially launched in June 2023 following peer-reviewed validation in Science (2018) and eLife (2021).
The company's product portfolio centers on VisionSort with supporting offerings including VisionCyte (high-throughput morphometric profiling), MorphoScan Cloud (cloud-based AI data analysis), Celluminate (fluorescent staining kits), consumables, and instrument service plans. ThinkCyte serves biopharmaceutical companies, academic research institutions, and healthcare organizations across three primary use cases: cell therapy R&D and manufacturing QC, drug discovery via phenotypic screening, and disease profiling including liquid biopsy and biomarker discovery. Named customers and partners include Broad Institute, the University of Tokyo, Kyoto University, Tokyo Science University, Sysmex Corporation, Hitachi, Vision Care Group, FIMM (University of Helsinki), Juntendo University, PhoreMost, Axcelead DDP, and the National Cancer Center Japan.
Revenue is generated primarily through direct enterprise sales of VisionSort instruments, supplemented by consumables, service plans, and an emerging SaaS stream via MorphoScan Cloud. The go-to-market combines a direct sales team in Tokyo and Redwood City with regional distributor relationships (e.g., CytoSens for Southern Europe) and a Premier Early Access Program that engages leading biopharma and academic centers prior to full commercial release. The company has raised approximately $76M USD in equity across seed, Series A, Series B, and Series C rounds through 2024, plus non-dilutive grants including a NEDO Unicorn Promotion Program award of up to ~$20M USD announced in August 2025, with total headcount currently reported at 51-100 employees.
ThinkCyte firmographics
Firmographics- Name
- ThinkCyte
- Legal name
- ThinkCyte K.K. (シンクサイト株式会社)
- Website
- https://thinkcyte.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ThinkCyte is a Japanese biotechnology company that develops and commercializes AI-powered, label-free cell analysis and sorting instruments based on its proprietary Ghost Cytometry technology. It serves biopharmaceutical companies, academic research institutions, and healthcare organizations across cell therapy, drug discovery, and disease profiling applications.
- Ownership category
- akta.pro rank
ThinkCyte industry classification
Industry- Product category
- Cell Analysis Instruments
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Optical Instruments & Lenses (3827), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF)
Keywords
Where ThinkCyte is headquartered
LocationHeadquarters
- HQ city
- Hongo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
ThinkCyte business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- VisionSort™ Platform Sales: ThinkCyte generates revenue primarily from the sale of its VisionSort cell analysis and sorting instruments to biopharmaceutical companies, academic research institutions, and healthcare organizations. The platform was commercially launched in June 2023 and has been adopted by major global biopharma companies and leading academic centers. Additional revenue comes from consumables (staining kits such as Celluminate) and instrument service/maintenance plans.
- Software as a Service (MorphoScan Cloud): MorphoScan Cloud provides cloud-based data analysis capabilities for VisionSort users, delivered as a SaaS platform with multi-user access and secure cloud storage. This represents an emerging software/subscription revenue stream complementing hardware sales.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
ThinkCyte product offering
Product offeringCore offering
ThinkCyte develops and sells VisionSort, the world's first AI-based dual-mode cell analysis and sorting platform that combines traditional fluorescence flow cytometry with high-dimensional morphological profiling. Powered by the proprietary Ghost Cytometry technology, VisionSort enables label-free cell sorting and unbiased single-cell profiling for biopharmaceutical companies, academic research institutions, and healthcare organizations. Revenue is generated from instrument sales, consumables, MorphoScan Cloud software subscriptions, and instrument service plans.
Product overview
ThinkCyte offers a unified product portfolio centered on VisionSort, its flagship AI-powered dual-mode cell analysis and sorting platform that combines fluorescence flow cytometry with morphological profiling. The platform is built on Ghost Cytometry, a proprietary AI-based label-free technology. Supporting products include VisionCyte (high-throughput morphometric analysis), MorphoScan Cloud (cloud-based data analysis software), and Celluminate (fluorescent staining kits). The company also provides consumables and instrument service plans.
Differentiator
Problem solved
Functional benefit
Brands
- VisionSort: Flagship AI-based dual-mode fluorescence and morphometric cell sorting platform combining traditional flow cytometry with morphological profiling and AI for label-free cell sorting and unbiased single cell profiling.
- VisionCyte
- MorphoScan Cloud
- Celluminate
- Ghost Cytometry
Products and services
- VisionSort The world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform that combines traditional fluorescence flow cytometry with high-dimensional morphological profiling. Enables label-free cell sorting and unbiased single-cell profiling for biopharmaceutical companies, academic research institutions, and healthcare organizations.
- MorphoScan Cloud Cloud-based platform for AI-driven cell morphology data analysis with secure cloud storage, multi-user access, and integrated analytical tools using supervised and unsupervised deep learning techniques for VisionSort-generated data.
- Celluminate Cell fluorescent staining kit for use with VisionSort and VisionCyte platforms, applicable to blood disorders, stem cell research, and aging-related disease studies where existing cell surface markers are insufficient for analysis.
- Consumables Reagents and consumables for use with the VisionSort platform including staining kits and other laboratory supplies.
- Instrument Service Service plans and technical support for the VisionSort instrument including maintenance, calibration, application support, and software upgrades for enterprise customers.
Quantifiable outcome
- VisionSort has been adopted by major biopharma companies and leading academic research institutes since its commercial launch in June 2023, with first installations completed in the US, Japan, Italy, and other key markets.
- +2 more outcomes
Companies that use ThinkCyte
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles5 records
ThinkCyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
ThinkCyte partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core.
- CytoSens (Italy)coreThinkCyte appointed CytoSens as the exclusive sales distributor for VisionSort in Italy, marking the first installation of VisionSort in Italy and serving as a gateway for expansion into Southern European markets including Spain and Portugal. CytoSens provides local sales, demonstrations, demos, and customer support using the installed VisionSort system.
- Institute for Molecular Medicine Finland (FIMM), University of HelsinkicoreThinkCyte and FIMM established a strategic research partnership to advance the understanding and treatment of blood cancers. The partnership leverages ThinkCyte's VisionSort platform with FIMM's Finnish Hematological Biobank containing clinically annotated leukemia samples collected at different disease and treatment stages. The goal is to characterize how cell morphology changes in different types of blood cancer to inform treatment selection, monitor disease progression, and identify novel drug targets.
- Juntendo UniversitycoreJuntendo University, Sysmex, and ThinkCyte entered into a collaborative research partnership to advance early detection and treatment of chronic myelogenous leukemia (CML). The research applies Ghost Cytometry to generate morphometric signatures from CML patient samples to identify, isolate, and characterize disease-driving cells for early diagnosis and better understanding of drug resistance mechanisms. The research is supported in part by Japan's Go-Tech Project.
- Axcelead Drug Discovery Partners (DDP)coreThinkCyte and Axcelead DDP entered into a joint research contract to develop new approaches to phenotypic drug screening. The partnership combines ThinkCyte's Ghost Cytometry with Axcelead DDP's phenotypic screening expertise and a diverse compound library of over 1.5 million candidate drugs. The goal is to develop a novel phenotypic drug discovery platform that can identify hit compounds missed by standard screening approaches that are biased by cell staining.
- PhoreMost Ltd.coreThinkCyte and PhoreMost (Cambridge, UK) entered into a strategic research partnership to advance AI-based drug discovery. The partnership combines ThinkCyte's Ghost Cytometry platform with PhoreMost's SITESEEKER® phenotypic screening technology (based on PROTEINi proprietary protein interference technology) to develop an entirely unique approach to high-content phenotypic screening for discovering novel drug targets and therapies for diseases with unmet clinical need.
- Vision Care GroupcoreVision Care Group (Kobe, Japan) and ThinkCyte established a research partnership to advance cell therapy for retinal disease. The partnership combines Vision Care Group's expertise in iPSC-based regenerative medicine for eye diseases with ThinkCyte's AI-driven label-free cell characterization and sorting technology. The goal is to improve manufacturing and pre-transplant testing for retinal cell therapy transplantation, developing transplantable cells with superior therapeutic outcomes without the need for antibody-based cell selection.
- Sysmex CorporationcoreSysmex and ThinkCyte entered into a joint development agreement and capital alliance in May 2021. The partnership aims to develop novel AI-based cell analysis technology for in vitro diagnostics (IVD) by integrating Sysmex's expertise in hematology and in vitro diagnostics with ThinkCyte's Ghost Cytometry technology. Sysmex invested equity in ThinkCyte as part of the capital alliance. The collaboration builds on prior joint research and represents a strategic partnership to commercialize AI-based diagnostic technologies globally.
- National Cancer Center Japan (NCCJ)coreThinkCyte and NCCJ were jointly awarded an AMED (Japan Agency for Medical Research and Development) grant to develop a high-accuracy method for isolating circulating tumor cells (CTCs) using Ghost Cytometry for genetic cancer profiling. The project, led by Dr. Shinji Kosaka at NCCJ in collaboration with ThinkCyte's Dr. Yoko Kawamura, aims to establish a liquid biopsy test for molecular profiling of cancer cells over time to improve patient prognosis and advance drug discovery.
- Hitachi, Ltd.coreHitachi and ThinkCyte entered into a collaboration to develop an AI-driven cell analysis and sorting system. The partnership combines ThinkCyte's label-free cell sorting technology with Hitachi's expertise in instrument reliability, mass production, and the regenerative medicine value chain. The goal is to enable stable, low-cost, large-scale production of cells for regenerative medicine and cell therapy by creating a reliable system for high-speed, label-free cell isolation that was previously difficult to achieve with existing cell sorting techniques.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
ThinkCyte competitors and assessment
Company assessmentBroad incumbents
- BD Biosciences (Becton, Dickinson and Company): BD is the dominant flow cytometry and cell sorting incumbent, selling the FACSDiscover and BD CellView image-enabled sorters that compete head-on with ThinkCyte's VisionSort. BD also offers broad biopharma and clinical diagnostics channels that ThinkCyte must penetrate to scale.
- Beckman Coulter Life Sciences (Danaher): Beckman Coulter's CytoFLEX and MoFlo Astrios cell sorters are standard equipment in academic and biopharma labs, directly comparable to VisionSort in the flow cytometry and cell sorting category that ThinkCyte targets.
- Thermo Fisher Scientific (Life Sciences): Thermo Fisher's Attune and Bigfoot cell sorters, combined with its global biopharma and academic distribution, are a major competitive force in the high-throughput cell analysis market that ThinkCyte targets.
Direct peers
- Cytek Biosciences: Cytek's full-spectrum flow cytometry instruments (Aurora, Northern Lights) and cell sorters serve the same biopharma and academic customers as ThinkCyte, and the company is also pursuing AI-driven high-content cell analysis — a direct competitive overlap with VisionSort's dual-mode morphological and fluorescence approach.
- Sony Biotechnology (Sony Group): Sony's CGX10 and MA900 cell sorters compete in the high-end cell sorting market and are increasingly incorporating imaging capabilities similar to ThinkCyte's Ghost Cytometry, putting them in direct competition for biopharma and academic accounts.
- Miltenyi Biotec: Miltenyi's MACS cell separation and sorting platform is a mainstay in cell therapy manufacturing and translational research — overlapping with ThinkCyte's cell therapy QC and regenerative medicine use cases (e.g., the Vision Care Group retinal cell therapy collaboration).
Emerging players
- 10x Genomics: 10x Genomics sells single-cell analysis platforms (Chromium, Xenium) that compete with VisionSort for high-content single-cell profiling budgets, particularly in drug discovery and disease profiling workflows where both companies offer AI-enabled analytics.
- NanoCellect Biomedical: NanoCellect's WOLF and NxT microfluidic cell sorters target the same gentle, label-free or low-pressure sorting niche that Ghost Cytometry addresses, making them a relevant emerging competitor in cell therapy and sensitive cell sorting.
- CytoReason: CytoReason applies AI to cell-based disease models and drug discovery data, overlapping with ThinkCyte's MorphoScan Cloud vision of AI-driven morphological data analysis for biopharma customers.
- Standard BioTools (formerly Fluidigm): Standard BioTools offers imaging mass cytometry and Hyperion systems for high-content single-cell analysis, providing a competing path for researchers who need multi-omic and morphological data — overlapping with ThinkCyte's disease profiling and biomarker discovery use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ThinkCyte social profiles
Digital presenceThinkCyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
ThinkCyte leadership team
Management profileNumber of profiles
Profiles7 records
ThinkCyte funding detail
Funding detailFunding overview
Funding rounds8 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ThinkCyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ThinkCyte
What does ThinkCyte do?
ThinkCyte develops and sells VisionSort, the world's first AI-based dual-mode cell analysis and sorting platform that combines traditional fluorescence flow cytometry with high-dimensional morphological profiling. Powered by the proprietary Ghost Cytometry technology, VisionSort enables label-free cell sorting and unbiased single-cell profiling for biopharmaceutical companies, academic research institutions, and healthcare organizations. Revenue is generated from instrument sales, consumables, MorphoScan Cloud software subscriptions, and instrument service plans.
Is ThinkCyte a public or private company?
ThinkCyte is a private company. It is classified as venture growth investor backed and is currently operating.
When was ThinkCyte founded?
ThinkCyte was founded in 2016. It employs 51 to 100 people.
Where is ThinkCyte based?
ThinkCyte is headquartered in Hongo, Japan, in the Asia region.
How does ThinkCyte make money?
Two revenue lines are on record. VisionSort™ Platform Sales are the primary driver. The others are software as a Service (MorphoScan Cloud).
Who are ThinkCyte's main competitors?
Broad incumbents on record are BD Biosciences (Becton, Dickinson and Company), Beckman Coulter Life Sciences (Danaher) and Thermo Fisher Scientific (Life Sciences). Direct peers are Cytek Biosciences, Sony Biotechnology (Sony Group) and Miltenyi Biotec. Emerging players are 10x Genomics, NanoCellect Biomedical, CytoReason and Standard BioTools (formerly Fluidigm).
Does ThinkCyte have an API?
No public API is recorded for ThinkCyte.
What industry is ThinkCyte in?
ThinkCyte's product category is Cell Analysis Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 541714 and its SIC code is 3827.